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1. Introduction 
Thanks to the changes in medicine, pharmacological treatment rapidly progresses into new 
fields. There is an emphasis on the development of treatment methods to eliminate 
underlying factors rather than to treat the symptoms of a disease. Therefore, research is 
increasingly utilizing knowledge from the field of genetics. Genetic mutation and deletion 
lead to many genetic disorders. Genetic disorders in metabolic pathways, regulation of cell 
cycle, ligand/receptor function, cell skeleton and extracellular proteins cause serious 
diseases (Yaron et al., 1997). 
Both genetic and acquired diseases may be treated using gene therapy. Genetic diseases are 
generally caused by deletion or mutation of a single cell. Conversely, in acquired diseases, a 
single gene cannot be defined as the sole cause of a disease. Gene therapy has increased in 
prominence, and has shown great potential in treating acquired and genetic diseases 
(Conwell and Huang, 2005). 
Gene delivery systems are categorized as: viral-based, non-viral-based and combined hybrid 
systems. Viral-mediated gene delivery systems consist of viruses that are modified to be 
replication-deficient, but which can deliver DNA for expression. Adenoviruses, retroviruses, 
and lentiviruses are used as viral gene-delivery vectors (Escors and Breckpot, 2010). 
Non-viral gene delivery systems were introduced as an alternative to viral-based systems. 
One of the most important advantages of these systems is improved transfection. Non-viral 
systems are categorized according to preparation, as physical or chemical types. The most 
common physical methods are microinjection, electroporation, ultrasound, gene gun, and 
hydrodynamic applications. In general terms, physical methods refer to delivery of the gene 
via the application of physical force to increase permeability of the cell membrane. In 
contrast, chemical methods utilize natural or synthetic carriers to deliver genes into cells. In 
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this method, polymers, liposomes, dendrimers, and cationic lipid systems are used as gene 
delivery systems (Miyazaki et al., 2006; Prokop and Davidson, 2007). 
2. Gene therapy 
This chapter provides general information on gene delivery systems, how they are used, 
their relative merits, and selection of the most appropriate methods for new studies on gene 
therapy. 
The drug sector is entering a new era that will enable treatment of the underlying cause 
rather than the symptoms of a disease. Many human diseases result from mutations or 
deletions, in genes, which lead to disorders in metabolic pathways, ligand/receptor function, 
cell cycle regulation, cell skeleton or extra-cellular protein structure and function (Sullivan, 
2003). With gene therapy, the disease can be treated by the injection of exogenous nucleic 
acid sequences designed to target the diseased tissues of the body (Yaron et al., 1997). 
Diseases that can be treated by gene therapy are categorized as either genetic or acquired. 
Genetic diseases are those which are typically caused by the mutation or deletion of a single 
cell. Conversely, a single gene is not defined as the sole cause of acquired diseases. 
Although gene therapy was initially used to treat genetic disorders only, it is now used to 
treat a wide range of diseases such as cancer, peripheral vascular diseases, arthritis, 
neurodegenerative disorders and AIDS (Mhashilkar et al., 2001). The expression of a single 
cell, directly delivered to the cells by a gene delivery system can potentially eliminate a 
disease. Prior to gene therapy studies, there was no alternative treatment for genetic 
disorders. Today, it is possible to correct genetic mutation with gene therapy studies 
(Sullivan, 2003).  
2.1. Chronology 
The term gene therapy was first introduced at the International Congress of Genetics (Yaron 
et al., 1997). The techniques utilized by Gregor Mendel in the 1850s, which were then 
developed by Ronald Fischer at the beginning of the twentieth century, formed the turning 
points in genetics. The work of both Mendel and Fischer laid the foundations of genealogy. 
The material they studied was later termed as gene by the Danish botanist Wilhelm 
Johannsen (Yaron et al., 1997). Towards the end of the 1970s, the background of the majority 
of genetic disorders was understood, and gene therapy came to the fore. The first gene 
therapy trial in humans was conducted at the beginning of the 1970s, and it was observed 
that naturally occurring DNA and RNA tumor viruses successfully delivered new genetic 
information to the genomes of mammal cells (Escors and Breckpot, 2010). 
Due to developments in the science of genetics, at the beginning of the twentieth century, it 
was understood that diseases such as hemophilia were genetic diseases. Similarly, it was 
found that diseases such as colon cancer, diabetes, and retinoblastoma were also genetic-
based diseases. In the 1980s, gene transfer to mammalian cells came to the fore after the 
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development of retroviral vectors (Yaron et al., 1997). In the mid-1980s, gene transfer to 
mammalian cells became a routine procedure. Retrovirus-based gene therapies brought 
significant advantages, as they can stably integrate their genomes to host-cell chromosomes. 
After the 1980s, DNA was defined as a genetic material. Later, it was structurally analyzed 
and further advances allowed the modification of genetic code. These discoveries on genetic 
material made cloning possible (Escors and Breckpot, 2010). 
In 2006, melanoma was successfully treated for the first time. The treatment used a 
retroviral formulation of melanoma antigen (MART-1)-specific T-cell receptor (TCR), which 
encodes α- and β- chains. In recent years, great advances have been made in gene therapy, 
ranging from somatic cloning and completion of human genome project to the discovery of 
microRNA-based gene-regulating systems (Escors and Breckpot, 2010). 
The use of non-viral gene delivery systems in gene therapy also significantly increased in 
recent years. Naked plasmid DNA, coated with gold particles was effectively introduced to 
cells using the non-viral gene gun technique. This technique was first used in plant cells in 
1987, and is today commonly used in mammal cells and tissues. One of the most 
successful current gene therapy techniques is hydrodynamic injection  (Willemejane and 
Mir, 2009). 
2.2. Gene delivery systems 
Gene delivery systems use various methods to allow uptake of the gene that has been 
selected to target the cell (Conwell and Huang, 2005). The successful design of a gene 
delivery system requires complete understanding of the interaction mechanism between the 
target cell and delivery system. Understanding intercellular traffic and targeting mechanism 
is the most important factor in designing a more effective gene delivery system. Cell 
targeting refers to delivery of the therapeutic agent to a specific compartment or organelle of 
the cell. It is the most commonly used mechanism in endocytosis gene therapy, particularly 
in cellular uptake of non-viral gene delivery systems (Prokop and Davidson, 2007). After the 
cellular uptake of the delivery system by endocytosis, cellular release takes place to initiate 
DNA transcription and translation, and to produce the related protein. A successful gene 
delivery procedure involves minimizing potential inhibitory inflammatory response while 
also overcoming certain barriers at each step of the gene delivery procedure, in order to 
optimize gene activity (Conwell and Huang, 2005).  
Viral gene delivery systems consist of viruses that are modified to be replication-deficient 
which were made unable to replicate by redesigning which can deliver the genes to the cells 
to provide expression. Adenoviruses, retroviruses, and lentiviruses are used for viral gene 
delivery. Viral systems have advantages such as constant expression and expression of 
therapeutic genes (Sullivan, 2003). However, there are some limitations that restrict the use 
of these systems, which particularly include the use of viruses in production, 
immunogenicity, toxicity and lack of optimization in large-scale production (Witlox et al., 
2007) (Figure 1). 
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Figure 1. Gene therapy strategies; mutation compensation, suicide gene therapy and immuno- 
potentiation (Witlox et al., 2007). 
Non-viral gene delivery systems were developed as an alternative to viral-based systems. 
One of the most important advantages of these systems is that they develop transfection. 
Non-viral gene delivery systems are divided into two categories: physical and chemical. 
Microinjection, electroporation, gene gun, ultrasound-mediated methods, and 
hydrodynamic systems are the most widely used physical methods. Physical methods 
involve the use of physical force to increase the permeability of the cell membrane and allow 
the gene to enter the cell. The primary advantage of physical methods is that they are easy to 
use and reliable. However, they also have the disadvantage of causing tissue damage in 
some applications. 
Chemical methods involve the use of carriers prepared from synthetic or natural 
compounds for gene delivery into the cell, including synthetic and natural polymers, 
liposomes, dendrimers, synthetic proteins, and cationic lipids. The biggest advantages of 
these systems are that they are non-immunogenic and generally have low toxicity.   
2.2.1. Viral gene delivery systems 
Since a large number of viruses have appropriate mechanisms for transfer of genetic 
material to the target cell, current gene technologies concentrated on the use of viral vectors 
that provide high transduction effectiveness and advanced level of gene expression. The 
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optimal design of a viral vector depends on the types of virus to be used (Wunderbaldinger 
et al., 2000). 
For safe application of in vivo gene therapy, firstly some problems should be eliminated. 
Therapeutic factors should only be expressed in related cell types, and should not cause any 
undesired effect in healthy cells (Yaron et al., 1997).  
2.2.1.1. Adenoviral systems 
Adenoviruses (Ad) were first discovered in 1953 by isolation from human adenoid tissue 
cultures (Campos and Barry, 2007; Majhen and Ambriovic-Ristov, 2006). They are 
commonly used as gene vectors (Dinh et al., 2005). C group adenoviruses Ad2 and Ad5 are 
the most widely studied adenoviruses. The capsid of an adenovirus determines virus 
tropism. Groups A and C–F first bind to highly-expressed coxsackie virus B-adenovirus 
receptor, and thus realize their high infectivity in many tissues. In contrast, group B binds to 
complement-regulatory protein CD46. Adenoviruses are replicated and produce virions, 
which contain the nucleus of the infected cell (Dinh et al., 2005). These vectors have the 
ability to be replicated, and purification of the vectors generally involves easier and shorter 
processes (Armendariz-Borunda et al., 2011). 
Adenoviruses are well-characterized, non-integrated, ~26–40 kb in length, relatively large, 
non-enveloped, linear dsDNA viruses coated with icosahedral particle, with a diameter of ~ 
950 Å (excluding elongated fiber proteins) and a molecular weight of approximately 
150MDa. They are unreplicated, and infect cells quickly. Adenoviral particles do not contain 
lipid or membrane; therefore they are stable in solvents such as ether or ethanol. The use of 
adenoviruses, which are one of the first developed vector systems for gene expression, is a 
great discovery (Campos and Barry, 2007). 
Adenoviruses have important characteristics, which make them indispensable for gene 
transfer. The most important ones are their well-known molecular biology; delivery capacity 
of foreign DNA fragments up to 36kb; and ability to transfect DNA into many cell types 
(Sullivan, 2003). 
Adenoviruses are one of the largest and most complex viruses, whose Ad structure was 
analyzed with cryo-electron microscopy and X-ray diffractometry. An Ad genome of 
approximately 36kb codes more than forty genomes; however, only 12 of these were 
demonstrated as the component of the virus particle. As seen in Figure 2 it was reported that 
crystal structures of single Ad proteins contained fiber knob, shaft, domains, penton base, 
hexon, and cysteine protease. Ad capsid consists of 252 sub-units called capsomeres, which 
contain 240 hexonproteins and 12 of the penton base. In addition, the capsid contains pIIIa, 
pVI, PVIII, and pIX proteins. Each of the 12 capsid corners contains penton bases wrapped 
by 5 hexons. The penton base serves as a hook for the fiber protein, which projects from the 
virus like an antenna. Fiber is a homotrimer, where 3 identical polypeptides bind in the 
same direction, and which contains 3 structurally and functionally different domains: N-
terminus, which binds the fiber non-covalently to the penton base; C-terminus, which gives 
the disc-like knob form, which is responsible for binding to the receptor; and the rod-like 
 Recent Advances in Novel Drug Carrier Systems 442 
shaft, which varies in length according to the serotype of the virus (Medina-Kauwe LK. 
2003; Majhen and Ambriovic-Ristov, 2006). 
 
Figure 2. Schematic of the adenovirus capsid. (A) Whole capsid identifying fiber, penton base, and 
hexon. (B) Enlargement of circled region in (A), showing homotrimeric fiber bound to homopentameric 
penton base. (C) Fiber monomer, identifying tail, shaft, and knob domains. Pictures are not drawn to 
scale (Medina-Kauwe LK. 2003). 
A viral genome is in a condensed state inside cell nucleus, together with protein V, VII and 
X, and the 5′ terminus of the AdDNA is covalently linked to a terminal protein (TP). The 
terminal protein (TP) functions as the initiation primer in viral DNA replication. An Ad 
genome consists of 5 early (E1A, E1B, E2, E3 and E4), 4 interim (IVa2, IX, VAI, VAII) and one 
late transcriptional unit. E1A is the first viral transcriptional unit, which will be expressed 
after entering the cell. E1A proteins activate other transearly transcription units, which will 
create an optimum medium for virus replication by causing the products to enter in S phase 
of the cell E1B proteins bind to p53, Bak, and Bax proteins, and allows the infected cell 
survive by inhibiting p53 dependent apoptosis. The E2A unit encodes the proteins that 
function in viral genome replication, including DNA polymerase, prethermal protein, and 
single-stranded DNA-binding protein. While the E4 transcription unit encodes the proteins 
that affect cell cycle control and transformation, E3 protein disrupts the immune response of 
the host and ensures the continuation of the infected cell (Majhen and Ambriovic-Ristov, 
2006). 
The nucleus is surrounded by an icosahedral capsid with a symmetrical structure, formed 
by the non-covalent interactions between 7 proteins (II, III, IIIa, IV, VI, VIII, and IX) (Smith 
et al., 2010). Adenoviral structural proteins are responsible for the stabilization of genome 
and encapsidation of the nucleoprotein nucleus. The icosahedral capsid consists of seven 
peptides:trimerichexons, which are found in complex form with three minor capsid 
polyproteins (VI, VIII and IX), which provides stabilization (II); pentonbase (III); receptor 
binding fiber (IV) and penton-bound protein which serves as a bridge between protein and 
the hexon base (III). The fiber consists of 3 domains which are tail in N-terminus, rod-like 
shaft and globular knob in C-terminus (Couglan et al., 2010). Adenoviruses enter target cells 
via receptor-mediated endocytosis. Instead of combining its own DNA with the genomes of 
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the host cell, the adenovirus, remains as an episome within the infected cell. This provides 
high efficiency (10); however, it should not be ignored, since it will restrict the longevity of 
expressed trans genes; in other words, protein expression will quickly cease (Yaron et al., 
1997; Muzzonigro et al., 1999). 
Penton and fiber proteins of virus capsid interact with the coxsackievirus-adenovirus 
receptor cell surface protein to provide cell binding. These proteins are then localized in 
clathrin-coated pits through NPXY motive of β3 and β5 integrin sub units of the cell. 
Dinamine, which is systolic GTPase, mediates cellular uptake of the virus into the cell via 
endocytosis by providing construction and development of clathrin-coated pits. Viral capsid 
proteins dissociate prior to endocytosis, and the pH value of the viral endosome decreases due 
to proton pumps. At pH 6.0, the virus has the ability to detach from the vesicle and enter the 
cytosol. Capsid proteins of the virus move towards the nucleus through microtubules and 
fragment in the following stages. Although a considerable part of the capsid proteins remain 
in the periphery of the nucleus, viral DNA crosses via nuclear pores (Ziello et al., 2010). 
For successful delivery of DNA to the nucleus, viruses must facilitate cell-specific binding, 
endocytosis internalization, propagation from endocytic vesicles to cytosol, delivery into 
cytoplasm, translocation from one terminus of the nuclear envelope to other, and finally 
expression of the delivered gene (Dinh et al., 2005). 
Direct injection or bolus delivery through inhalation is the easiest form of viral delivery. 
However, since the virus will spread from the injection area, a high dose is required to achieve 
therapeutic effectiveness. The spread of the virus from the injection site limits the regional 
effectiveness and immune response. Adenoviral vectors can be targeted via selective 
modification of coat proteins. There is a relatively high level of protein expression following 
the transduction, equal to approximately 35% of total cellular protein (Zhang et al., 2009). 
Adenoviruses have many natural properties that enable them to be used as a vector for on 
colitic, vaccine, or gene therapy. Non-enveloped viruses can be kept in lyophilized form in a 
stable state inside a flacon tube or capsule; they can be transported without cold chain; by 
mediating in high transduction effectiveness in dividing and non-dividing cells, they can 
form 104 virus particles per infected cell (Khare et al., 2011). Adenoviruses achieve suitable 
transduction through a high level of expression and become beneficial in in vivo conditions 
(Muzzonigro et al., 1999). 
Adenoviruses have been one of the most promising methods for high effectiveness in in vivo 
gene therapy. For example, following systemic vector delivery, transduction levels of 
hepatocytes were observed by adenoviral systems. These are some of the most effective 
vectors for gene delivery to various organs; however, they have very significant 
disadvantages. Some target cells have low ratios of appropriate primary and/or secondary 
adenoviral receptors, and this requires a high dose of vector application to cause target-cell 
cytotoxicity. Additionally, non-discriminating tropism of the virus can also lead to 
transduction to untargeted cells (Reynolds et al., 1999). The most serious problem in the use 
of Ad vectors is their tendency to cause strong immune and inflammatory responses at high 
doses (Navarro et al., 2008). 
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2.2.1.2. Retroviral systems 
Retroviruses are diploid, single-stranded, circular-enveloped RNA viruses of the family 
Retroviridae, with a genome of 7–11 kb, and a diameter of approximately 80–120 nm (Osten 
et al., 2007; Escors and Brecpot, 2010). The Retroviridae family is divided into two sub-
families: Orthoretrovirinae and Spumaretrovirinae species (Osten et al., 2007). Retroviruses 
cause diseases such as AIDS, leukemia, and cancer; however, their use as a vector in gene 
therapy brought new developments in treatment (Pages and Danos, 2003). 
The ability of retrovirus-based gene delivery vectors to carry foreign genetic material was 
first realized in the early 1980s (El-Aneed, 2004; Escors and Brecpot, 2010). Retroviruses are 
viruses that integrate with host genome to produce viral proteins (gag, pol, env) that are 
extracted during gene delivery (El-Aneed, 2004). Retroviral vectors have the capacity to 
delivery DNA up to 8 kb (Navarro et al., 2008). The most commonly used retroviruses are 
the Moloney murine leukemia virus species, which have the capacity to deliver exogenous 
genetic material up to approximately 9 kb (Muzzonigro et al., 1999).  
A virion nucleus consists of circular or triangular gag-encoded capsid proteins. They are 
coated with gag-encoded nucleocapsid protein. The nucleus contains pol-encoded enzymes, 
reverse transcriptase, and integrase. Retrovirus genomes have various characteristics. For 
example, these viruses are diploid in the real sense, and their genomes are produced by 
cellular transcriptional mechanism. In addition, these viruses require cellular (tRNA) for 
replication (Luban, 2000). The genome of these (+) sense RNA viruses is not directly 
processed as mRNA immediately after infection Considering the structure of the genome, 
retroviruses are categorized as either simple or complex forms. Simple and complex 
retroviruses encode gag (group-specific antigen), pro (protease), and pol (polymerase) 
genes; complex retroviruses also encode a large number of additional genes. Retroviruses 
were the first viruses to be modified for gene delivery, and have also been used in the 
majority of clinical trials of gene therapy (Hu and Pathak, 2000). 
Most of retroviral vectors used in clinical studies are based on the Moloney murine 
leukemia virus (MMLV). MMLV is a well-studied and characterized virus; its genome 
encodes three polyproteins that are required in trans form for replication and packaging: 
gag, pol and env (Escors and Brecpot, 2010). 
An ideal retroviral vector for gene delivery should be cell-specific, regulated, and safe. 
Effectiveness of delivery is important, as it will also determine the effectiveness of therapy 
(Hu and Pathak, 2000). Retroviruses have a lipid envelope. In order to enter a host cell, they 
use the interactions between cellular receptors and virally encoded proteins, which are 
embedded in the membrane (Hu and Pathak, 2000). Combination of chimeric envelope 
protein with viral particles allows the retrovirus to bind receptor-positive target cells (Yi et 
al., 2011). SU in the virion surface binds to CD, which is a cell-surface protein expressed by 
some T-cells and is found in macrophages. Binding to CD4 induces some changes in the 
envelope protein (SU) of the domain of epidermal growth factor (EGF), which allows for 
interaction with chemokine receptors (CKR). CKRs are a family of cell-surface-G-proteins 
functioning as receptors to stain molecules called chemokines. 
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Infusion of viral and cellular membranes starts the internalization of the viral nucleus (Yi et 
al., 2011); the viral envelope combines with the cell membrane. Envelope glycoprotein (Env) 
of retroviruses is responsible for determining tropism. Binding of Env to cellular receptor 
and fusion of viral and cellular membranes are the first stages of infection. Trials that 
targeted retroviruses by adding single-stranded antibodies or Env cell-binding ligands 
showed limited success. The addition of such large ligands to Env protein prevents Env 
from binding to the virion (Bupp and Roth, 2002). Env protein takes a particle-coated 
structure and releases the viral nucleus into the cytoplasm. Single-stranded DNA gets 
reversely transcripted to double-stranded DNA in the nucleus (Osten et al., 2007; Karlsson et 
al., 1987). Viral RNA is reverse transcribed to a DNA copy using virally-encoded reverse-
transcriptase enzyme in the virion (Hu and Pathak, 2000). Retroviruses follow a different 
replication cycle through transformation of single-stranded RNAs into double-stranded 
DNA in the infected cell. Viral DNA synthesis takes place in cytoplasm by virion-dependent 
DNA polymerase, which is termed reverse transcriptase. Viral DNA enters the nucleus, 
where takes the ring form for the first time, and serves as a draft for RNA synthesis (Olsen 
and Swanstorm, 1985). The first DNA product is a linear double layer molecule, which 
forms during DNA synthesis. Within the nucleus, some linear DNA is turned into many 
different forms of ring DNA; these mainly contain two copies of LTR units in tandem, or a 
single copy of LTR unit (Olsen and Swanstorm, 1985). The end of each LTR unit creates 
short, deficient repetitions; this represents the strand domain required for this integration 
(Olsen and Swanstorm, 1985), and is delivered to the nucleus. This delivery takes place 
through cell division for oncoretroviruses, and through active transport for lentiviruses. 
Here, lentiviruses are observed to be more advantageous than oncoretroviruses, as they have 
the ability to deliver genes to non-dividing cells. When viral DNA enters the nucleus, it 
integrates with the DNA of the host cell (provirus). Retroviruses introduce their genetic 
material to the host cell genome in a stabile manner during mitotic division. Since these types 
of retroviruses only transfer genes to dividing cells, many procedures that utilize retroviruses 
are applied ex vivo. However, more recent lentiviral-based retroviral vectors reduce these 
restrictions (Muzzonigro et al., 1999). Most retroviruses infect cells that can be actively divided 
during mitotic division. This property protects normal tissue, and although it naturally targets 
the tumor, all tumors contain non-dividing cells in G0, which is the resting phase of the tumor 
cell cycle (Hu and Pathak, 2000; Kitamura et al., 2003; El-Aneed, 2004) (Figure 3). 
Infected cells are then transcribed and spliced. Full-length viral RNA (which is the RNA that 
encodes all proteins) is delivered to cytoplasm and translated; other cellular procedures are 
modification and delivery of RNA from the nucleus (Hu and Pathak, 2000). Spliced full-
length viral RNA is  packaged into viral particles. Retroviruses are RNA viruses that are 
replicated over integrated DNA intermediate products. Retroviral particles surround two 
copies of full-length viral RNA, containing all of the genetic information required for virus 
replication, with capsid (Hu and Pathak, 2000). Virologic and genetic studies indicated that 
specific packaging of retroviral genomic RNA was carried out through the interaction with 
the nucleocapsid (NC) domain of Gag polyprotein. Retroviral NC domains are generally 
very simple, and contain one or two zinc knob motifs consisting of C-C-H-C sequences. Zinc 
knobs form metal-coordinated reverse turn, stabilized by NH-S hydrogen bonds. Most 
retroviral zinc knobs contain a hydrophobic cut on the surface of the mini-globular domain, 
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Figure 3. Structures of retrovirus vectors. (A) Basic structure of retrovirus vectors and two transcripts 
from the vector. In the replication competent MMLV, the Gag-Pol and the Env proteins are translated 
from the genomic RNA and the subgenomic RNA, respectively. The subgenomic RNA is a spliced form 
RNA, and the splicing occurs from the splice donor site (SD) to the splice acceptor site (SA). Both 5′ 
and 3′ LTRs consist of U3, R, and U5 regions. Ψ = packaging signal; Δgag = truncated gag sequence. 
(B) Structures of versatile pMXs-derived vectors. LTR = long terminal repeat; Ψ = packaging signal; 
MCS = multi-cloning site; IRES = internal ribosomal entry site; GFP = green fluorescent protein' 
neor = neomycin-resistant gene; puror = puromycin-resistant gene. (C) Structures of pMXs, pMYs, and 
pMZs vectors. The 5′ LTR, primer binding site (PBS), and the extended packaging signal of pMXs are 
derived from the MFG vector. PBS used in pMYs and pMZs are derived from MESV (murine embryonic 
stem cell virus) and binds tRNA-glu instead of tRNA-pro. MCS is designed for cDNA library 
construction and is preceded by triple stop codons (not shown). White box = MMLV LTR; gray 
box = PCMV LTR; hatched box = MPSV LTR or SFFVp LTR. MCS = multi-cloning site (Kitamura et al., 
2003).  
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recognizing the specific structure of RNA or DNA. Base N- and C- terminal tails of 
nucleocapsid domains are conformationally indurable (Miyazaki et al., 2011). Retroviral 
genome packaging is generally localized between the binding donor (SD) region and the gag 
start codon in the 5′ head region. It should be noted that the packaging sign generally 
coincides with the dimerization region, which indicates that packaging combines with 
genome dimerization (Miyazaki et al., 2011). Inhibition of genome dimerization through 
addition or deletion of mutations at dimer initiation sites (DIS) causes a significant decrease 
in genome packaging. Studies of mutant viruses containing two retroviral genomes showed 
that these were non-covalently dimerized in progen viruses. 5′ untranslated region (UTR) 
packages monomeric genome, which indicates that the genome packaging procedure occurs 
via the interaction of two 5′ UTR (Miyazaki et al., 2011). Virion maturation occurs by the 
budding of the particle from the cell (Escors and Brecpot, 2010). The translational 
mechanism of the host synthesizes and modifies viral proteins. Newly synthesized viral 
proteins and full-length RNAs combine to produce a new virus form, which will be budding 
from the host cell (Hu and Pathak, 2000).  
A retrovirus infects the target cell by providing interaction between viral envelope protein 
and cell surface receptor on the target cell. The virus then internalizes to the place where its 
single-stranded RNA turns into double-stranded DNA. Double-stranded DNA is delivered 
to the nucleus and integrated to the host cell genome there. Many types of retrovirus types 
require degradation of mitosis and then the nuclear envelope for the arrival of a viral 
genome within the nucleus (Robbins and Ghivizzani, 1998). 
Stable binding of viral DNA to the host genome is advantageous because it will provide 
long-term expression of transgenes required for therapeutic effect. However, one of the 
disadvantages of current retroviral transfer systems is that they are not specific to types of 
target cells (Yi et al., 2011). 
One of the most important properties of retroviruses is that they can integrate a reverse 
transcribed genome to the host cell chromosome (Miyazaki et al., 2011). 
Unlike adenoviral vectors, retroviral vectors realize transfection through transgene 
integration to the target cell genome. However, transgene expression ceases within a few 
days or weeks. Retroviral vectors reveal gene transfer that is unsuitable for many cells in in 
vivo conditions, and this partly stems from rapid inactivation of the human complement 
system. This silencing is not well characterized; however, it appears as a result of 
methylation in DNA or promoter regions, or participation of splice region to condensed 
chromatin (Reynolds et al., 1999; Navarro et al., 2008). 
The ability of retroviruses to enter their genomes to host DNA enables them to make stable 
modifications to the life cycle of the host cell. This stability is greater than viruses such as 
adenovirus, herpes simplex virus (HSV), and papilloma virus, which remain episomal 
(Robbins and Ghivizzani, 1998).  
2.2.1.3. Lentiviral systems 
In recent years, studies mainly concentrated on the use lentiviral vectors. Lentivirals are 
viral systems without small, retrovirus-like viral proteins and no capacity for replication; 
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they provide gene delivery to non-dividing cells. This characteristic property is an 
advantage for various gene therapy applications used in targeting in post-mitotic and highly 
differentiated cells. The most important advantage of lentiviruses compared with other 
retroviruses is their ability for gene transfer to non-dividing cells (Escors and Brecpot, 2010; 
Yi et al., 2011; Matrai et al., 2009; Freed, 1997). This characteristic is believed to be related to 
the pathogenic characteristics of lentiviruses, which infect terminally differentiated cells of 
monocyte/macrophage lineage (Freed, 1997). For this reason, lentiviral vectors can be used 
for transgene expression to neuron cells (Yi et al., 2011). 
Genome of lentiviruses have a more complicated structure; they contain accessory genes 
which regulate viral gene expression, control combination of infectious particles, modulate 
viral replication in infected cells, and are associated with the continuance of infection 
(Howarth et al., 2010). In other words, the fact that it contains regulatory and accessory 
genes apart from gag, pol and env, requires lentiviruses to adopt a more complex form 
(Osten et al., 2007). For example, HIV-1 is one of the most widely used lentiviral vectors, and 
contains six accessory genes (tat, rev, vif, vpr, nef, vpu) (Osten et al., 2007; Yi et al., 2011). 
These proteins are involved in all steps of cell cycles, which are termed: budding, 
maturation, and integration. In addition to helping combination of virions, these proteins 
ensure nuclear export and transcription ratio of RNA (Yi et al., 2011).  
HIV infects CD4-positive T lymphocytes and macrophages (CD4 antigen acts as a primer 
surface receptor for HIV-1), and causes chronic immune deficiency, known as acquired 
immune disorder syndrome (AIDS). HIV-1 genome additionally contains 2 regulatory genes 
(tat and rev), and 4 accessory genes (vpr, vpu, vif, nef). The lenti viral genome is 9.2 kb in length. 
Tat protein increases transcriptional activity in 5′ LTR of integrated provirus from promoter 
regions. Rev protein transports non-spliced HUV mRNA from the nucleus. In general, 
accessory proteins increase virulence against the host organism. Development of HIV-1-based 
vectors was first achieved by utilizing the abilities of lentiviral vectors of infecting post-mitotic 
cells. The design of other retrovirus-based vectors, such as self-inactivating MoMLV vectors, 
can be directly transferred to lentiviral vectors. In the most recent generations of HIV-1-based 
vectors, all accessory genes and the regulatory tat gene are deleted (Osten et al., 2007). In the 
self-inactivating (SIN) expression vector, the U3 promoter region is deleted from the 3’LTR. 
This region was copied to the 5′ end of dsDNA during reverse-transcription. Therefore, SIN 
modification results in transcriptional inactivation of the integrated provirus, which allows for 
the restriction of the likelihood of recombination with latent retroviral sequences and 
mobilization of latent retroviral sequences in the host cell genome (Osten et al., 2007).  
Tropism of lentiviral vectors depends on the type of envelope protein used for viral 
production (Escors and Brecpot, 2010). The use of heterologous Env proteins is called 
pseudo typing. The most widely used Env protein is “vesicular stomatitis virus glycoprotein 
(VSV-G)”. This protein permits the virus high titration values via ultracentrifugation and a 
wide tropism (VSV-G binds to suitable phospholipid component of plasma membrane) 
(Osten et al., 2007).  
Lentiviral vectors do not require degradation of the nuclear membrane for integration. 
Lentiviruses that are encoded with the Gag matrix protein integrase enzyme and vpr protein 
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interact with the nuclear import mechanism of the target cell and manage active transport of 
pre-integration complex via nucleopores. This characteristic enables transfection to non-
dividing cells and, in conclusion, “complex retroviruses” become suitable for use as gene 
transfer vectors, particularly for post-mitotic cells like neurons (Howarth et al., 2010). 
Receptors have been defined for many retroviruses. The best-characterized example is CD4 
molecule, which serves as a receptor for lentiviruses including HIV (Freed, 1997). 
Frequently, pseudotype lentiviral vectors are formed by “vesicular stomatitis virus” 
envelope (VSV-G). VSV-Gis a glycoprotein that interacts with the phospholipid component 
of a number of receptors or cell membrane. VSV-G offers large host-cell range and high 
vector particle stability, which are attractive characteristics for ex vivo gene modification. 
However, restriction of infection to specific cells, which is called transduction altargeting, is 
effective and reliable and critical in the case of in vivo gene delivery. In addition, it is the key 
to increase therapeutic effectiveness, reduce adverse effects, and reducing the required 
amount of the vector. Two methods can be used to achieve this: (a) benefiting from natural 
characteristics of existing viral proteins, (b) using gene engineering to continue, stop or 
increase the original tropism of the vector (Escors and Brecpot, 2010).  
Recently-developed lentiviral gene transfer systems have many characteristics of retroviral 
systems. A viral genome integrates with host chromosomes, and genes that are desired to 
remain permanently are placed (Yi et al., 2011). 
2.2.2. Non-viral gene delivery systems 
The basic concept underlying gene therapy is that it develops gene expression to specific 
cells in order to treat human diseases or for transfer of genetic material to inhibit the 
production of a target protein (He et al., 2010). 
In theory, viral carriers can achieve rapid transfection of foreign material spliced to viral 
genome with high transfection ratio. However, many studies that used viral vectors 
reported unsatisfactory results, due to the immunologic and oncogenic adverse effects of 
these vectors. On the other hand, non-viral vectors have many advantages, such as easy of 
fabrication, cell/tissue targeting, and low immune response. The biggest disadvantage of 
non-viral vectors in clinical use is low transfection efficiency (He et al., 2010). Therefore, the 
most important points that should be taken into account in gene therapy are the 
introduction of the gene into the cell and increasing transfection efficiency. Using 
transfection, cells are induced for the production of chemicals used in pharmacological 
arrangements like hormone replacement or specific protein production (Godbey and Mikos, 
2001). Naked DNA molecules cannot effectively enter to the cell due to their hydrophilic 
structures and large size resulting from negatively-charged phosphate groups. In addition, 
they are easily fragmented by nuclease enzymes. Therefore, the biggest difficulty in gene 
therapy is the development of physical methods to ensure gene transfer to target cells of the 
gene delivery vectors and delivered gene (Al-Dosari and Gao, 2009). 
As seen in Figure 4, natural and synthetic polymers are used to prepare non-viral gene 
delivery systems. Compared to viral delivery systems, non-viral carriers are less toxic and 
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immunogenic. Another advantage of non-viral vectors is ease-of-production (DeLaporte et 
al., 2006). Much of the previous research found that non-viral systems were less effective 
than viral systems. However, in gene therapy conducted with physical methods, the 
effectiveness of gene transfection and therapy increased, and the duration of gene 
expression was extended significantly in clinical terms (Al-Dosari and Gao, 2009).  
 
Figure 4. Modular design of non-viral vectors schematic. Modules associated with vector design are: 
vector backbone (grey), functional groups for regulating environmental interactions (purple), and 
intracellular trafficking (red). The vector backbone, typically containing polymers, lipids, or 
polysaccharides, is designed for DNA binding and complexation, which can protect against nuclease 
degradation, create a small, less negatively charged particle that can be internalized by cells, and facilitate 
some intracellular trafficking. The function of the vector backbone is being augmented by the attachment 
of groups that address the extracellular and intracellular barriers. The environmental functional groups can 
serve to limit interactions with serum components, promote specific cell binding or tissue targeting, or 
facilitate interactions with the extracellular matrix or biomaterials. The intracellular functional groups aim 
to enhance nuclear accumulation of the DNA either by facilitating endosomal escape, movement along the 
cytoskeleton, or nuclear pore trafficking. The individual modules can be assembled in different ways (a–c) 
for complexation with DNA (green), which may affect the structure and function of the resulting non-viral 
vector. (d) Schematic illustrating the distribution of the modules and DNA throughout the vector cross 
section, with the desired organization of functional groups regulating the environmental interactions 
presented primarily on the exterior and the groups for intracellular trafficking protected within the vector 
interior for activity following internalization. (e) Vectors are internalized by endocytosis and must 
subsequently escape the endosome for transport to the nucleus. Additionally, the modular components 
must dissociate from the DNA to allow for transcription (DeLaporte et al., 2006). 
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A number of barriers need to be overcome in order to increase the effectiveness of non-viral 
vectors in humans. These barriers are classified as production/formulation/storage; 
extracellular barriers; and intracellular barriers (Davis, 2002). Anatomic barriers are 
extracellular matrixes coating the cells, which prevent direct transport of macromolecules to 
target cells through epithelium and endothelial cell sequences. Phagocytes like Kupffer cells 
in the liver and residential macrophages in the spleen are responsible for theclearance of 
DNA-loaded colloidal particles in blood circulation. Similarly, nucleases found in blood and 
extracellular matrix cause free and unprotected nucleic acids to be rapidly inactivated 
following systemic application. The most critical barrier to effective DNA transfection was 
regarded as the transition of plasma membrane. Typically, naked nucleic acids cannot cross 
cell membrane by cellular uptake mechanisms such as endocytosis, pinocytosis, and 
phagocytosis without application of physical methods or being loaded to a carrier (Al-Dosari 
and Gao, 2009). There is a substantial body of research on developing effective physical, 
chemical, and biological systems to deliver transgenes into the cell to provide appropriate 
expression (Gao et al., 2007). Physical approaches, including electroporation, gene gun, 
ultrasound, and hydrodynamic delivery are based on the application of a force to increase the 
permeability of the cell membrane and promote intracellular gene transfer. In chemical 
applications, synthetic or natural carriers are used to transport transgenes to the cells. An ideal 
gene delivery system should meet 3 criteria: The carriers should protect the transgene from 
nuclease enzymes inside intracellular matrixes; should transport the transgene from plasma 
membrane to the target cell nucleus; and should not cause any toxic effect (Gao et al., 2007). 
Two of the most important advantages of synthetic carriers are that they do not display 
immunogenicity, and large-scale production is easy. Furthermore, the size of the gene to be 
delivered does not reduce efficiency of these systems. Even mammalian artificial 
chromosomes of 60 megabase were successfully transfected by these types of carriers 
(Schatzlein, 2003). 
Non-viral vectors can trigger an inflammatory response, since they do not provide a specific 
recognition; they are much less dangerous than viral vectors in terms of antigen specific 
immune response. However, although non-viral vectors seem to be more suitable, there are 
some important points to be contemplated in vector design. Non-viral vectors should be 
designed according to specific cell targeting; cellular uptake and cellular release should be 
optimized; and potential immune response should be minimized (Conwell and Huang, 
2005; Mrsny, 2005). 
2.2.2.1. Physical methods 
Gene Gun 
Delivery with gene gun method is also termed ballistic DNA delivery or DNA-coated 
particle bombardment, and was first used for gene transfer to plants in 1987 (Al-Dosari and 
Gao, 2009; Lin et al., 2000). This method is based on the principle of delivery of DNA-coated 
heavy metal particles by crossing them from target tissue at a certain speed. The particles 
achieve sufficient speed due to a pressurized inert gas (generally helium). Generally, gold, 
tungsten or silver microparticles were used as the gene carrier (Mhashilkar et al., 2001; Al-
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Dosari and Gao, 2009; Miyazaki et al., 2006). Momentum allows penetration of these 
particles to a few millimeters of the tissue and then cellular DNA release (Gao et al., 2007). 
These particles typically have a diameter of 1µm. Due to its small size, the particle easily 
penetrates the cell membrane and can transport DNA into the cell. At this point, DNA 
separates from the carrier particle and can be expressed (Lin et al., 2000). 
Gas pressure, particle size and dose frequency are critical factors in determining the degree 
of tissue damage and penetration effectiveness of the application (Al-Dosari and Gao, 2009). 
Gene-gun-based gene transfer is a widely tested method for intramuscular, intradermal and 
intratumoral genetic immunization (Miyazaki et al., 2006). Numerous animal tests and 
clinical trials indicated that this method caused a greater immune response than 
microinjection, even in low doses (Al-Dosari and Gao).  
The advantages of gene gun over other in vivo gene delivery systems are as follows: [1] It 
does not use toxic chemicals or complex biological systems, [2] delivery is achieved without 
the need for a receptor, [3] DNA fragments of various sizes, including large ones, are 
transported, [4] there is no need to introduce foreign DNA or protein, [5] it has high 
repeatability, [6] production of heavy metal particles is easy (Lin et al., 2000). However, in 
this method, gene expression is short-term and low (Mhashilkar et al., 2001).  
Electroporation 
The future of gene therapy requires the advancement of effective and non-toxic 
polynucleotide gene delivery mechanisms. Electroporation includes controlled electric 
application to increase cell permeability. Electroporation was first developed in 1960s, with 
studies on the degradation of cell membrane with electric induction. Neumann et al., first 
reported transfection of eukaryotic culture cells through electroporation in 1982. In many 
subsequent studies, transfection was performed on animal and plant cells via 
electroporation (Al-Dosari and Gao, 2009; Somiari et al., 2000). 
Electroporation introduces foreign genes into the cell by electric pulses. In this method, 
pores are formed on the membrane surface to enable the DNA to enter the cell. Pore 
formation occurs very rapidly, in approximately 10 nanoseconds. The size of the electric 
pore is estimated to be smaller than 10 nm radius. If the molecule is smaller than the pore 
size (as in oligonucleotides and chemical compounds), it can be transferred to the cell 
cytosol through diffusion (Somiari et al., 2000; Miyazaki et al., 2006). In addition to passive 
diffusion, loaded molecules and ions can be transported from the membrane via 
electrophoretic and electro-osmotic means via the effect of electric regions. The pores close 
following cellular uptake of DNA. In recent years, in vivo electroporation became common 
in nucleic acid vaccines and improving non-viral gene therapy. There are critical steps 
defined for transportation via in vivo gene delivery with electroporation. The first step is 
fusing together, attachment or proximity between the cell membrane and nucleic acid. The 
second step is adding nucleic acid to the membrane, which is immediately followed by the 
third step, involving the delivery of nucleic acid from the membrane. The delivery 
procedure results in decreased pore size and permeability (Somiari et al., 200).  
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In vivo electroporation technique is a generally reliable method that is more efficient than 
other non-viral systems. When the parameters are optimized, this technique is equally 
effective as viral vectors. In addition to local injection and electroporation, it was previously 
shown that in vivo electroporation can be applied in localized form after the injection of 
plasmid DNA (Al-Dosari and Gao, 2009).  
There are some difficulties in in vivo applications of electroporation. There is an effectiveness 
region of approximately 1 cm between the electrodes, and this makes transfection of the 
cells in large regions of the tissues difficult. It is difficult to use in internal organs, and 
surgery is required to implant electrodes. High temperature due to high voltage application 
can cause irreversible tissue damage. The application of high voltage to cells can affect the 
stability of genomic DNA (Al-Dosari and Gao, 2009; Gao et al., 2007). 
Ultrasound 
Ultrasound has many clinical advantages as a gene delivery system, due its easy and 
reliable procedure (Pitt et al., 2004; Ferrara, 2010). In recent years, it was found that 
microbubbles applied by ultrasound increased gene expression. Microbubbles or ultrasound 
contrast agents decrease cavitation threshold with ultrasound energy. In many applications, 
perfluoropropane-loaded albumin microbubbles (Mallinckrodt, San Diego, USA) were used. 
The microbubbles were modified with plasmid DNA before the injection and then 
ultrasound was applied (Niidome and Huang, 2002). 
Ultrasound has been used for therapeutic purposes for more than a half century, even before 
the use of ultrasound for diagnosis and imaging purposes. In diagnostic use, low-intensity 
ultrasound is used to prevent energy accumulation in tissue causing biological effects. 
Conversely, therapeutic applications are based on the principle of intensification of 
ultrasound energy within the tissue (Frenkel, 2008). 
After the discovery of the applicability of ultrasound to gene therapy at the cellular and 
tissue level, this was taken one step further with physical methods. Reporter gene 
expression, where naked DNA is used, advanced for10 times thanks to this discovery. The 
transfection efficiency of this system is based on frequency, time of ultrasound treatment, 
the plasmid DNA mount used, etc. In conclusion, size and local concentration of DNA plays 
an important role in the effectiveness of transfection (Gao et al., 2007). 
Hydrodynamic therapy 
Hydrodynamic gene delivery is based on the principle of understanding the characteristics 
and structure of capillaries, an understanding of the dynamic characteristics of the fluids 
passing through blood veins (Suda and Liu, 2007). Hydrodynamic gene delivery uses the 
hydrodynamic pressure created by the injection of the large volume of DNA solution with 
blood pressure inside veins (Suda and Liu, 2007), and thus the permeability of the capillary 
endothelium increases and pores form in the plasma membrane encircling parenchyma cells 
(Gao et al., 2007; Suda and Liu, 2007). DNA or other related molecules can reach the cell 
from these pores. Membrane pores are later closed, and these molecules are retained within 
the cell. In hydrodynamic gene therapy, the principle reason for targeting parenchyma cells 
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is that capillary endothelium and parenchyma cells are closely related, and when the 
endothelial barrier is breached, this allows DNA to easily reach parenchyma cells. In 
addition, the capillary’s thin wall structure has a stretchable and easily fragmented structure 
(Suda and Liu, 2007). The effectiveness of hydrodynamic procedure depends on capillary 
structure, the structure of the cells encircling capillaries, and the hydrodynamic force 
applied (Gao et al., 2007; Suda and Liu, 2007).  
2.2.2.2. Chemical methods 
Polymers 
Polymers are long-chained structures composed of small spliced molecules called 
monomers. Polymers that are composed of a repeated monomer are called homopolymers, 
while those composed of two monomers are called copolymers. Natural and synthetic 
polymers are used in drug delivery systems. Biodegradable and non-biodegradable 
polymers are used according to the type of controlled release mechanism. Biodegradable 
polymers are non-water soluble, and undergo chemical or physical change in biologic 
environments (Tuncay and Calis, 1999). Polyamides, dextran, and chitosan are examples of 
biodegradable polymers. On the other hand, non-biodegradable polymers are not degraded 
in biological environments; hydrophilic polymers are hydrogels, which are non-water 
soluble and swell in water, while hydrophobic polymers are non-water soluble and do not 
swell. Examples of hydrophilic hydrogel polymers include polyvinylalcohol, 
polyvinylacetate, polyethyleneglycol, polyacrylic acid, polyhydroxyethyl methacrylate, and 
polymethacrylic acid. Examples of hydrophobic polymers include silicones, and 
polyethylene vinyl acetate. Polymers such as ethyl cellulose (EC), hydroxypropyl methyl 
cellulose (HPMC), cellulose acetate phthalate (CAP), and eudragit derivatives are commonly 
used in controlled release systems (Tuncay and Calis, 1999). 
Selection and design of a polymer is difficult due to structural differences; achieving the 
desired chemical, mechanical, and biological functions requires understanding of the 
characteristics and surface of a polymer. For polymer selection, in addition to its 
physicochemical characteristics, characterization of extensive biochemical characteristics and 
preclinical tests are required to demonstrate its reliability (Pillai and Panchagnula, 2001). 
The physical properties of a polymer carrier, such as hydrophilicity, surface charge, 
permeability and diffusibility, biocompatibility with tissue and blood (Pillai and 
Panchagnula, 2001). 
For successful delivery, polymers should package DNA in small sizes. Thus, extracellular 
and intracellular stability of DNA is increased; cellular uptake by endocytosisis enabled; 
and, by transporting it to the nucleus, the active form of DNA can be released within the 
nucleus (Mrsny, 2005).  
Polymeric gene transporters deliver genetic material through electrostatic interactions with 
nano-sized polyplexes for gene therapy (Kim et al., 2011). 
A synthetic gene delivery system: [1] should protect the negatively-charged phosphate DNA 
skeleton against anionic cell surface from load repulsion, [2] should be condensed to suitable 
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length intervals of DNA with a macromolecular structure for cellular internalization 
(condensing at nanometer size for receptor compatible endocytosis or condensing at 
micrometer size for phagocytosis); and [3] should protect DNA from all extracellular and 
intracellular nuclease degradations. To meet this need, researchers concentrated on three 
strategies: electrostatic interaction, encapsulation, and adsorption (Wong et al., 2007). 
Electrostatic interaction 
The majority of polymeric vectors presently in use form complexes with negatively charged 
DNA by electrostatic interaction. All polymers have amino groups. At adequate nitrogen–
phosphate ratio, the polymer and the DNA form nanocomplexes, which allows both cellular 
DNA uptake and also protects the DNA from nuclease enzyme (Wong et al., 2007). 
Encapsulation  
An alternative to electrostatic condensation of DNA is encapsulation of DNA with a 
biodegradable polymer. Polymers that have an ester linkage in their structures (like 
polyesters) are hydrolytically degraded to short oligomeric and monomeric compounds, 
which are more easily discharged from the body. Furthermore, the degradation mechanism 
and DNA release can be controlled by changing the physicochemical characteristics and 
composition of the polymer. DNA is protected from enzymatic degradation by 
encapsulation (Wong et al., 2007) (Figure 5). 
 
Figure 5. Gene packaging—The three main strategies employed to package DNA are via (1) electrostatic 
interaction, (2) encapsulation within or (3) adsorption onto biodegradable nano- or microspheres (Wong 
et al., 2007). 
 Recent Advances in Novel Drug Carrier Systems 456 
Adsorption 
Alternative DNA packaging methods, such as adsorption techniques, were developed to 
overcome the limitations of encapsulation methods. DNA adsorption represents the 
combination of the above mention two models. In this method, DNA is conjugated to the 
surface of biodegradable cationic particles, or is electrostatically adsorbed due its negative 
charge. This method prevents the DNA from being exposed to heavy encapsulation 
conditions, and also increases rapid release DNA (Wong et al., 2007). 
Adsorption methods attracted much research interest, as it does not cause immunogenicity, 
does not require the integration of exogenous genes to host chromosomes, is a simple and 
cheap method, and is suitable for effective gene delivery. However, low transfection 
efficiency, some cytotoxic effects, and in vivo instabilities are still significant restricting 
factors in gene therapy. One of the strategies to solve these problems is the synthesis of 
biologically degradable polymers (Kim et al., 2011). 
Liposomes 
Liposomes are colloidal drug delivery systems. They are biologic membrane-like sacs in 
sphere form, formed by one or more lipid layers, and include an aqueous phase. The 
phospholipid phase consists of principle components like aqueous phase and cholesterol. 
Liposomes are classified according to the number of layers they contain. The advantages of 
liposomes include effectiveness at small doses, extended dosing interval, and ideal transport 
for active substances with a short half-life. Cellular uptake mechanism of active substances 
in liposomes can be categorized as endocytosis, combination by melting, and adsorption. 
Liposomes are used for application of carcinogenic, antifungal, antiparasitic, antiviral, and 
anti-inflammatory drugs, hormones, DNAs, and cosmetics (Bogdansky, 1990). 
Cationic lipids, which are used for the entrance of plasmid DNAs in the cell, have been 
studied for more than 20 years. During this period, many cationic liposome formulations 
were developed, and were tested as nucleic acid transported in animals and human with 
phase I and phase II studies. When compared to other gene delivery systems such as viral 
vectors and transfection agents, cationic liposome delivery systems are more easily 
formulated and cause no biological damage like viral vectors (Dass and Choong, 2006). 
Critical parameters that determine the behavior of liposomes in in vitro and in vivo 
conditions include size, number of layers, and surface charge. Unilamellar or mutilamellar 
vesicles can be produced depending on the preparation method; the diameter of these 
vesicle ranges from 25 nm to 50 µm (Bogdansky, 1990). 
Liposomes are divided into three categories according to their charges: cationic, anionic, or 
neutral. Compared to viral vectors, liposome delivery systems are non-pathogenic and non-
immunogenic, with easy of preparation. However, the most important disadvantage of 
liposomes is short gene expression time and low transgene expression level. Since liposomes 
are generally non-toxic and non-immunogenic structures, they are considered reliable 
carriers for gene therapy. Liposome-based gene delivery was first reported by Felgner 
(1987). In the 1990s, liposomes were used in numerous cationic lipid gene therapy tests. 
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Liposomes are not as effective as viral vectors in in vivo gene delivery, and it is generally 
difficult for them to transfect targeted gene to selected cells (Miyazaki et al., 2006). 
Dendrimers 
Dendrimers were first defined in the late 1970s and early 1980s. Dendrimers consist of 
symmetrical branches projecting from a central core (Dufes et al., 2005; Genc, 2008; Bulut 
and Akar, 2012). Dendrimers are 10–200 Angstrom in diameter; they are repeating, 
branched, large spherical molecules, and have functional groups on their surface that can be 
used as a building block to connect many biological materials (Ward and Baker, 2008). These 
functional groups determine the variability of dendrimers, whereas branching provides the 
growth of the structure (Dufes et al., 2005; Bulut and Akar, 2012). As seen in Figure 6, the 
most important advantages of dendrimers are conjugation of a large number of different 
molecules on the dendrimer surface, and the conjugation of molecules that will be used for 
diagnosis and treatment (Ward and Baker, 2008; Dufes et al., 2005). 
 
Figure 6. Dendrimer structure. The stepwise synthesis of dendrimers means that they have a well 
defined hierarchical structure. This hypothetical dendrimer is based on a core with three covalent root 
attachment points but other common cores have di- or tetracovalent cores. The valency of the core 
dictates the number of linked dendrons and the overall symmetry of the molecule. The dendrons are 
synthesised by covalent coupling of the branch units. For each additional layer or generation that is 
being added to the structure the reaction sequence is repeated. In this case the units have two new 
branching points at which additional units can be attached. (The generation count is not always 
consistent: normally generation 0 refers to the core while sometimes it is used to describe the dendrimer 
after the first reaction cycle.) The number of branching points, branching angles, and the length of the 
branching units determine to what extent each generation increases molecular volume vs. surface area. 
For the higher generations the density of the terminal groups reaches a point where for steric reasons no 
groups can be added (starburst effect). Dendrimers of higher generation also have a typical molecular 
density profile under favourable conditions; the high peripheral molecular density establishes a steric 
outer shell and the lower density at the centre creates cavities which can accommodate guest molecules. 
(Dufes et al., 2005). 
The degree of polymerization of dendrimers is represented by the number of generations 
(G) of repeated branching cycles during synthesis. Generation number can be easily 
identified by calculating number of branching points from the core to the outer surface. 
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The number of branching points increases proportional to dendrimer growth. For 
example, a dendrimer with no connection points is termed zero generation (G-0) (Bulut 
and Akar, 2012).  
Equal layer groups of dendrimers with an equal number of layers are highly suitable for use 
in drug delivery due to their perfect encapsulation characteristics and highly controllable 
chemical behaviors. Drugs can be encapsulated in a dendrimer or can electrostatically or 
covalently connect to functional groups on the surface (Ward and Baker, 2008; Bulut and 
Akar, 2012). On the other hand, targeted drug delivery can be achieved by covalent 
conjugation of the targeting agent to functional groups of dendrimers (Ward and Baker, 
2008). 
Although the toxicity of dendrimers that form complexes with DNA generally decreases, 
toxicity and cellular effects of free dendrimers should be taken into account (Dufes et al., 
2005). 
Cationic lipid compatible systems 
Felgner et al. pioneered cationic lipid-based gene transfer (Felgner et al., 1987; Al-Dosari and 
Gao, 2009). Today, hundreds of lipids have been developed and tested for gene transfer. 
Lipid-based systems consist of a positively-charged hydrophilic head and hydrophobic tail 
structure.  
Most common hydrophilic head groups are primary, secondary, tertiary amines, or 
quaternary amine salts. These positively charged sections connect to negatively charged 
phosphate groups in nucleic acid. The hydrophobic tail consists of aliphatic chain, 
cholesterol, or steroid rings. The connection region between hydrophilic and hydrophobic 
sections consists of the bonds that affect biodegradability ratio, such as ether, ester, 
carbamate, or amid (Al-Dosari and Gao, 2009; Uyechi-O’Brian and Szoka, 2003). 
Each lipid has a different sized head group and hydrocarbon tail length, and these 
characteristics have a significant impact on the formation of DNA–lipid complexes and 
intake by the cell (Balasz and Godbey, 2010). The transfection effectiveness of cationic lipids 
varies according to the structure of the lipid and the charge ratio used to form the DNA–
lipid complex. Compared to negatively-charged DNA, a positively-charged lipid 
spontaneously forms structures called lipoplexes. In lipoplex structure, the DNA molecule is 
encircled by positively-charged lipids, which protect it from extracellular and intracellular 
nucleases. In addition, due to their positive charges, lipoplexes electrostatically interact with 
the cell membrane and thus cellular uptake is achieved (Al-Dosari and Gao, 2009; Uyechi-
O’Brian and Szoka, 2003). 
Cationic lipids such as N-[1-(2,3-dioliloksi)propyl]-N,N,N-trimethlammoniumchloride 
(DOTMA), [1,2-bis(oliloxy)-3-(trimethlamonnium) propane] (DOTAP), 3β[N-(N_,N_-
dimethlaminoethane)-carbamile] cholesterol (DCChol) and dioctadecylamidolysisspermine 
are used to prepare lipid carriers (Balasz and Godbey, 2010).  
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The aim of cationic lipid-based gene therapy is to transport plasmid DNA to the cell and 
thus to achieve the desired protein/peptide transcription and translation. DNA–lipid 
complex is internalized into the cell through the vesicular path, which is followed by the 
release of cell cytoplasm of DNA from the lipoplex. Some fractions of the released DNA are 
transported to the nucleus (Uyechi-O’Brian and Szoka, 2003). Strong DNA–cationic lipid 
complexes alone are insufficient for gene transfer; however, DNA release before or after 
transport to the nucleus is critically important (Khalid et al., 2008). Lipid–cationic lipid ratio, 
cationic lipid–DNA ratio and DNA mount presented to the cell are important parameters 
that significantly influence transfection efficiency (Hofland et al., 1996). 
Although gene expression is provided by cationic lipids, for clinical benefit, the 
effectiveness, expression time and degree of gene transfer were not found to be adequate. 
The most significant disadvantages of cationic lipids are structural instability and 
heterogeneity, inactivation in blood, low effectiveness, and weak targetability when 
compared to other systems (Navarro et al., 2008). 
Cationic lipid-based transfection systems are easy to prepare and reliable; they also have 
low immunogenicity, and there is no need to classify the size of DNA which will be 
transported (Mortimer et al., 1999). Many cationic lipid-DNA based systems are effectively 
taken up by endocytosis; however, the mechanism of DNA release from endosome and 
translocation to the nucleus are not well known (Mortimer et al., 1999).  
2.3. The use of gene delivery systems in treatment 
2.3.1. Cancer  
Any change in the structure of genes that cause diseases is called mutation. In a mutated 
cell, variations occur in the sequence of nucleotides. As a result, chemical substances that are 
produced under the control of the gene have abnormal structure and function. If the gene is 
associated with the growth, differentiation, or division of cells, then the mutation might 
cause cancer (Wang et al., 2012). There are two main groups of genes responsible for formation 
of cancer. These are oncogenes and tumor suppressor genes. Oncogenes are mutated versions 
of normal genes that are responsible for controlling cell growth. After mutation, they compel 
the cell to become a cancer cell. There are more than 100 known oncogenes, most of which 
were identified in human tumors. The “ras gene” is the most widely known and most 
commonly studied of these genes. After mutation, the ras gene initiates division and cancer 
formation in cells with the “ras protein” it forms (Luo et al., 2012). 
Tumor suppressor genes normally inhibit cell division and tumor development in cells. The 
mutated forms of these genes cannot inhibit cell division, and instead cause tumor 
formation. Among these genes, the RB and P53 genes are the most widely known. These 
genes show their effect with p-RB protein and P53 protein, which are produced under their 
control. Normally, these proteins inhibit DNA replication and cell division, and regulate 
apoptosis. If the created genes are mutated, these proteins lose their activity and 
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uncontrolled cell division occurs, which results in cancer development. It was indicated that 
RB protein was inactive in approximately 40% of human cancers. Similarly, it was  
found that P53 gene had an abnormal structure in 50% of all tumors (Morandell & Yaffe, 
2012). 
Gene therapy is based on the principle of replacing damaged genes in diseased cells with 
corresponding healthy genes that were prepared outside the body. This approach is the 
most difficult type of gene therapy. Successful treatment involves healthy genes, which are 
prepared out side the body, targeting specific cells in the body via certain transporters 
(carriers). Current technology has simplified the process of preparing healthy genes.  
However, the subsequent process of targeting cells remains imperfect (Lagisetty & Morgan, 
2012). 
In addition to the correction of defective genes, gene therapy includes other treatment 
principles. In a different method, cancer patients were injected “cytosinedeaminase” 
enzyme, which is not normally produced in humans, via viral carriers,thereby allowing this 
enzyme to be synthesized in tumor cells (Logue & Morrison, 2012). The drug 5-FC is injected 
at high doses with no adverse effects; this is converted to 5-FU in tumor cells by cytosine 
deaminase enzyme. Using this method, effective levels of drug activation are achieved 
without damaging healthy cells. 
In a similar method, carrier viruses injected with “thymidinekinase enzyme gene” found 
in the herpes simplex viruses reach cancer cells and produce thymidine kinase enzyme in 
these cells. This enzyme enables the drug ganciclovir, which has no adverse effects on  
normal body cells, to be active in tumor cells and destroy cancer cells (Etienne-Grimaldi et 
al., 2012) 
Another treatment approach involves inhibition of oncogene proteins that were mentioned 
above. Oncogenes cause cancer formation via the proteins they control. If the production of 
these proteins is inhibited, their cancer-causing effects will be reduced. One example is the 
farnesyltransferase enzyme, which plays a role in the formation stages of RB protein. It was 
reported that new tumor formation was inhibited in patients who were injected with drugs 
that inhibited the function of this enzyme (Logue & Morrison, 2012). Cancer treatment is the 
most studied application of gene therapy. A large number of genetic changes occur by the 
transformation of a normal cell to a neoplastic cell (El-Aneed, 2004). 
Tumor suppressor genes eliminate cancer cells through apoptosis, whereas oncogenes 
accelerate proliferation. For this reason, apoptotic genes and anti-oncogenes are frequently 
used in cancer treatment. In addition to oncogenes and tumor suppressor genes, 
chemotherapy and gene therapy were combined via a ‘suicide gene’ strategy. A suicide gene 
encodes an enzyme that does not belong to mammals, and this enzyme converts non-toxic 
product into active cytotoxic metabolite in cancer cells. Tumor suppressor genes, anti-
oncogenes, and suicide genes target cancer cells at the molecular level. Generally the genes 
that encode cytokine revive immune response to cancer cells (Wang et al., 2012). 
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Transformation of a normal cell to a neoplastic cell occurs by multi-mutationary changes of 
the cells at the genetic level. Due to the complicated nature of cancer, cancer gene therapy 
involves many therapeutic strategies. These strategies can be analyzed according to two 
categories: immunogenic and molecular (El-Aneed, 2004). 
2.3.2. Immunologic approach 
The human immune system has two pathways to respond to foreign antigens. The first 
pathway includes antibodies secreted by B cells following activation of membrane 
immunoglobulin via (B cell receptor)-antigen connection. Antibodies are water-soluble 
proteins that move within the circulatory system to reach the target antigens. T cells, the 
second immune pathway, directly interact with antibodies without secreting antibody. T 
cells can produce multiple immune reactions, including cytotoxic effects (Lagisetty & 
Morgan et al., 2012).  
Cancer cells are immunogenic in nature with their cancer antigens, which are intracellular 
molecules. Therefore, cellular immunity (T-cell mediated), is more important than humoral 
immunity (B-cell mediated) (Restifo et al., 2012). Normal immune response is not sufficient 
to eliminate tumor cells. The ability of cancer cells evade immune-system responses is 
associated with secretion of immunosuppressive factors, down-regulation of antigen 
expression or MHC (major histocompatibility complex) molecules, and co-stimulation 
deficiency. One of the common genetic immunotherapy strategies includes transfer of 
immune-stimulating molecular genes like cytokines. Immune response is created by the 
activation of interleukin-12 production by tumor cells with numerous components of 
immune system, particularly including cytotoxic T lymphocytes and natural killer cells 
(McDonald et al., 2012). 
Another immunologic approach involves in vitro manipulation of the antigen-presenting 
cells to produce active tumor antigens. Dendritic cells are the strongest antigen-presenting 
cells (El-Aneed, 2004). Application of antigen-encoding genes via direct vaccination might 
induce the desired immune response to cancer cells. When injected subcutaneously or 
intramuscularly, DNA enters local cells like fibroblast and myocytes, and antigen is 
subsequently produced and secreted. Antigen-presenting cells move towards lymphoid 
organs where new antigens will be caught and the desired immune response will be 
initiated (El-Aneed, 2004). Another method to increase the specificity of chemotherapy 
might be enzyme-encoding enzyme-activate prodrug therapy, which converts non-toxic 
products into specific and toxic metabolites (Altaner, 2008). This approach is known by 
many different names, including enzyme prodrug therapy in gene management; suicide 
gene therapy or enzyme prodrug therapy in virus management; and gene prodrug 
activation therapy (Scheier et al., 2012). All of these expressions define the same two-step 
treatment process. The first step involves the targeting and transport of the foreign 
enzyme to the tumor via various pathways. In the second step, non-toxic prodrug is 
applied and converted to active systolic metabolite. In in vivo approaches, expression of 
foreign genes does not occur in each cell of the target tumor. As a result, the active drug 
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can enter the transduced cell and cell deaths take place, including the cells which do not 
express enzyme. This procedure is also termed the bystander effect or neighbor cell death 
effect. In addition, dead cells can induce host immune response due to T cells and NK 
cells. This therapeutically beneficial effect is known as the slight bystander effect. To 
increase the effectiveness of enzyme-activated product therapy, therapeutic genes in the 
vector should be expressed at a sufficiently high ratio to achieve effective prodrug 
transformation; it should remain as active as possible in order to support the killing 
mechanisms of the produced systolic metabolite, and the suicide gene should be 
specifically targeted only to the tumor. These arrangements will also reduce adverse 
effects (Altaner, 2008). 
2.3.3. Cardiovascular disorders 
Recombinant adenovirus is one of the most practical vectors for localized gene therapy. In 
addition, these vectors allow for tissue-specific delivery, and are suitable for re-targeting. 
Bispecific antibodies were used to coat adenovirus particles by connecting the antibody 
ligand on the cell receptor surface. Genetic modifications also include gene modifications for 
some viral coat proteins to change tropisms of adenoviruses (Ji et al., 2012). 
Antiviral vectors are the most recently developed vectors; they are HIV-based and generally 
used for HIV treatment. These vectors have the ability to transfect non-dividing and 
dividing cells. The effectiveness and reliability of these cells are currently being analyzed 
(Kozarsky, 2001). 
2.3.3.1. Angiogenesis  
One exciting recent development is that blood circulation can be provided to ischemic 
tissues. The development of new blood veins was observed in the region of endothelial 
growth factor (VEGF) expression (Katz et al., 2012). Gene transfer has advantages for protein 
therapy, and the use of permanent VEGF is preferred. This method can be fulfilled by a 
single injection of gene-transfer vector; however, transgene expression of VEGF should last 
for a limited period, because long-term unregulated VEGF expression might cause abnormal 
angiogenesis. Therefore, rapid gene expression obtained from adenoviral and plasmid 
vectors are among the ideal vectors for local delivery of VEGF gene by direct injection 
(Kozarsky, 2001; Katz et al., 2012). 
2.3.3.2. Cardiac failure 
Treatment of cardiac failure by gene therapy is still limited, due to the need to determine 
suitable transgenes and develop effective gene delivery methods to the myocardium. Genes 
can be directly transported to the heart. However, if these genes have to be transported to 
larger regions, as in the case of cardiac failure, this method is not regarded as successful. 
Another method involves transporting gene delivery vectors to coronary veins via a 
catheter; however, some catheter materials inactivate recombinant adenovirus (Kozarsky, 
2001; Kairouz et al., 2012). 
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2.4. Pulmonary disorders 
According to some authors, lungs are ideal organs for gene therapy. However, cystic fibrosis 
and α1-antitripsin deficiency are the only common disorders with known genetic 
background for which existing treatments are not curative. Although cystic fibrosis is the 
first target for pulmonary gene therapy, this method is used to treat many acquired diseases, 
mainly cancer (Davies et al., 2003). 
After the discovery of CTFR in 1989, considerable new progress was made to improve gene 
transfer system for somatic gene therapy of cystic fibrosis. Cystic fibrosis affects 
approximately1 in 2500 newborns, which makes it the most common recessive genetic lethal 
disorder (Davies et al., 2003). Even a copy of a single normal SF gene is sufficient for normal 
function (Klink et al., 2004). Therefore, somatic gene therapy is relatively straightforward. 
The only requirement is to provide a cell affected by a gene which makes CFTR protein 
expression (94). CFTR is cAMP-regulated chloride channel in epithelium cells. Dysfunction 
of CFTR arises from production deficiency, problems in transport of apical membrane of the 
cell to the effective region, or due to functional defects (Davies et al., 2003). Air tract 
epithelium is the most important target among lung diseases that cause mortality and 
morbidity. In order to address this aim, many gene delivery systems were developed and 
their effectiveness in vitro and in vivo was analyzed. 
The use of adenoviral vectors gave rise to safety concerns due to low transduction 
effectiveness and increasing inflammation in human lungs. Tests with cationic liposomes 
showed low toxicity and effectiveness (Klink et al., 2004).  
Some individuals have to be overcome to perform gene therapy. Mucociliary clearance is the 
primary one of these individuals. Air tract secretions and the mucociliary clearance system 
act as significant barriers to exogenous gene transfer. The epithelia of a healthy respiratory 
system create a thin mucus layer required for normal cilia function; however, this layer 
inhibits gene transfer by cationic liposomes (Davies et al., 2003). 
Similarly, a potential gene transfer agent has to overcome the barrier formed by secretions in 
order to enter the cell. The glycocalyx structure and endocytosis ratio of a cell were defined 
as the factors that restrict the effectiveness of gene transfer. A number of intracellular 
process, including endosomal system, cytoplasmic delivery, and the entrance to the nucleus 
serve as barriers to successful gene transfer. Similarly, host immune response causes 
problems in the application of gene transfer agents to lungs (Davies et al., 2003). 
Adenovirus/CFTR was applied to the nasal epithelia of three patients to treat cystic fibrosis. 
No viral replication was observed, but mild inflammation was reported. PD returned to 
normal baseline values in all three patients (Davies et al., 2003). However, one of the 
problems of this vector system is that low expression levels of viral gene wastes leads to 
cytotoxic T-cell response that targets vector-containing cells. The fact that adenoviruses are 
generally air tract pathogens is a both advantageous and disadvantageous. Many potential 
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receivers have circulating antibodies that reduce vector effectiveness and T-cell response. 
Most importantly, systemic application of adenoviral vectors causes acute and potentially 
life-threating inflammation responses due to activation of antigen-presenting cells (Klink et 
al., 2004). On the other hand, when compared to other gene delivery systems, lentiviral 
vectors are advantageous. Lentiviral vectors are integratable retrovirus derivatives with a 
high cloning capacity. When suitable regular sequences such as LCS (locus control sections) 
are used, stable and cell-specific expression can be achieved. When envelope proteins of 
pseudo-written lentiviral vectors are applied to apical surface with vesicular stomatitis 
virus, it is not possible to effectively transduce polarized air tract epithelia. Retroviral 
vectors, pseudo-written with apical membrane-connecting envelope proteins, are used to 
overcome this problem (Klink et al., 2004).  
The first clinical trial of liposome-compatible CFTR gene transfer was reported in 1995. This 
method involves direct application of DC-Chol/DOPE/CFTR to the nasal epithelia of SF 
patients. No adverse clinical effects were observed, and nasal biopsy analyses showed no 
histologic change. Specific mRNA and plasmid DNA were found in five out of eight 
patients who received CFTR gene vector (Klink et al., 2004). 
3. Conclusion 
Current gene delivery systems are divided into three categories: viral-based, non-viral 
based, and combined hybrid systems. Viral gene delivery systems consist of viruses that are 
modified to be replication-deficient which can deliver genes to the target cells to provide 
expression. Although viral systems have many advantages, such as long-term expression, 
and the effectiveness and expression of therapeutic genes, they also have various 
disadvantages. These disadvantages include risks due to working with viruses, optimization 
problems when producing large batches, and problems of immunogenicity and toxicity. To 
date, adenoviruses, retroviruses, and lentiviruses have been used as viral gene carrier 
vectors. Non-viral systems include physical and chemical methods. In its broadest sense, 
this refers to delivery of the gene into the cell by applying a physical force in order to 
increase the permeability of the cell membrane. The most common physical methods are 
microinjection, electroporation, ultrasound, gene gun, and hydrodynamic delivery. 
Chemical methods use natural and synthetic compounds are to deliver the gene into the cell. 
The gene delivery system generally includes polymers, liposomes, dendrimers, and cationic 
lipids. Non-viral vectors have many advantages, such as easy of synthesis, effective 
targeting of cell/tissue, low immune response, and potential to use plasmid at desired 
molecular weight. The biggest disadvantage of non-viral vectors in clinical use is low 
transfection efficiency. A large number of viral and non-viral gene delivery systems have 
been developed. Both systems have many advantages and disadvantages. Hybrid systems 
were developed to combine the advantageous parts of both the individual systems, while 
minimizing their respective disadvantages, thereby producing a gene therapy with higher 
effectiveness and low toxicity. The biggest advantage of hybrid systems is that they are less 
toxic than viral systems, and are not as low-efficient as non-viral systems. 
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